Combination therapy with losartan/ hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan
|
|
- Julianna Shepherd
- 5 years ago
- Views:
Transcription
1 464285TAK Therapeutic Advances in Cardiovascular DiseaseH Suzuki, Y Shimada 2012 Therapeutic Advances in Cardiovascular Disease Original Research Combination therapy with losartan/ hydrochlorothiazide for blood pressure reduction and goal attainment in a real-world clinical setting in Japan Ther Adv Cardiovasc Dis (2012) 6(6) DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Hiromichi Suzuki, Yukio Shimada and Kenji Fujiwara Abstract: Objective: When physicians prescribe a new antihypertensive drug, they do not know the extent of the drug s effect on lowering blood pressure. To resolve this dilemma, a Web-based program was constructed for real-time entry and analysis of treatment. This observational study evaluated the efficacy of losartan/hydrochlorothiazide (Lo/HCTZ) in lowering blood pressure (BP) and achieving BP target values. Methods: Physicians prescribed Lo/HCTZ for patients with hypertension who failed to achieve target BP values of < 140/90 mmhg and < 130/80 mmhg in patients with diabetes or chronic kidney disease, respectively, with antihypertensive drugs including an angiotensin receptor blocker. Results: From December 2006 to December 2009, the data of 88,254 patients were entered into this database, and the data of 24,825 subjects were analyzed. At the first visit, a total of 88,254 patients received a first prescription of Lo/HCTZ daily. Among these, at the end of the present analysis, 24,825 (28%) outpatients had a follow-up visit at 1 month and 20,726 (23%) outpatients had a follow-up visit at 6 months. The prevalence of hypertensive patients achieving systolic blood pressure (SBP) control (< 140 mmhg) increased over time from 6.9% to 54.3% in females and 6.1% to 52.3% in males (p < 0.05). At the start of the study, the levels of SBP were significantly highest in the eldest patients ( 75 years) followed by the group of years and lowest in the youngest patients ( 64 years). However, at the end of the study, there were no differences in levels of SBP among the three groups. Conclusions: This Web-based system may provide useful information when a new drug is first released into the market. Treatment with Lo/HCTZ enabled a substantial proportion of hypertensive patients to achieve the recommended goal of < 140/90 mmhg. Keywords: age, chronic kidney disease, diabetes mellitus, gender, hypercholesterolemia Introduction Major clinical trials have clearly shown that reduction of an elevated blood pressure (BP) is associated with a reduced risk of cardiovascular (CV) events, regardless of the antihypertensive agents used [Sawicki and McGauran, 2006]. Angiotensin receptor blockers (ARBs) have recently been established as a major class of antihypertensive agents on the basis of their powerful effect on BP, excellent tolerability, and pleiotropic end-organ protective effects [Sica, 2006]. In spite of these properties, treatment only with ARBs does not always achieve the BP target. To achieve further reduction of BP as a key goal of antihypertensive therapy, the availability of a fixed dose of hydrochlorothiazide (HCTZ) combined with ARBs provides an aggressive tactic for lowering BP [Dusing, 2010]. Losartan (Lo)/ HCTZ is an effective combination therapy, with which BP is lowered to a greater extent than Lo or HCTZ alone in hypertensive patients [Keating, 2009]. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, Lo-based therapy was associated with a lower Correspondence to: Hiromichi Suzuki, MD, PhD Department of Nephrology, Saitama Medical University, 38 Morohonngo, Moroyama machi, Iruma gun, Saitama, , Japan iromichi@saitama-med. ac.jp Yukio Shimada, MD, PhD Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan Kenji Fujiwara, MSc CareNet, Inc., Tokyo, Japan 237
2 Therapeutic Advances in Cardiovascular Disease 6 (6) incidence of CV morbidity and mortality than atenolol-based therapy, mainly as a result of a reduced risk of stroke [Dahlöf et al. 2002]. However, the efficacy and advantages of combining Lo and fixed-dose HCTZ have not been clearly shown. In addition, physicians may be uncomfortable with unknown effects of new drugs on patients. For example, when physicians prescribe a new antihypertensive drug, they do not know the extent of the ensuing effect of BP decrease. Recently a Web-based program was constructed for real-time entry, and analysis of treatment and adverse effects [Volpe et al. 2012]. Using this Website, physicians can learn the effects of new drugs on patients and compare the data of other physicians. If the data registered through the Website are analyzed, real usage of a new drug will provide valuable information for general physicians. However, according to several studies [Boersma et al. 2003; Bramlage et al. 2007; Mancia et al. 2007], the percentage that achieved the target BP of < 140/90 mmhg still remains low. In the present study, the objectives were threefold: (a) to report trends over time in hypertension control with Lo/HCTZ in combination; (b) to provide the data of a Web-oriented BP control system; (c) to determine the proportion of patients who achieved BP targets of < 140/90 mmhg in the general population, and < 130/80 mmhg in hypertensive patients with diabetes mellitus (DM) and/or chronic kidney disease (CKD) in a realworld setting. Methods This was a retrospective, noncontrolled analysis of data derived from a large, cross-sectional, Webbased clinical database collected by physicians. Physicians did not receive any specific indications on digit preferences, or how to submit clinic data and BP levels in the database. Care-Net, Inc. has developed a Web-based drug-monitoring system, aimed at local collection, central recording, and real-time analysis of drug prescriptions for a new drug. The physician has her/his own identification number and password, which are required for any log-in to the system and Web-based drug prescription. Clinical data, including anthropometric parameters, BP levels, and heart rate are also required. In the light of these considerations, and cognizant of the potential limitations of findings derived from a Web-based, noncontrolled drug-monitoring system, we retrospectively analyzed and summarized the main data derived from the registry on Lo/HCTZ prescriptions written by 3401 general practitioners collected in 6 months between December 2006 and December The operation center identified the physician. If the physician was not identified, the registration was cancelled. After online registration, an identification (ID) number and password given to all physicians were required whenever they accessed the Website. CareNet provided a comprehensive electronic patient record system, in which the participants were able to register their patients. In a single interface, patients information including ID number, age, gender, underlying diseases, past history, BP levels, laboratory tests including semiquantities of urine protein, serum creatinine, total cholesterol, fasting blood glucose, hemoglobin A1c, and uric acid were registered. Patient selection Patients eligible for this study were aged over 40 years, with a BP higher than 140/90 mmhg, or 130/80 mmhg (patients with DM or CKD) in spite of treatment with antihypertensive drugs that included ARBs. After registration, the study committee evaluated the subjects registered by the physicians and then communicated a final decision to the physicians. After the start of treatment with Lo/HCTZ, the physicians were encouraged to enter information of BP every month during the next 6 months. At the end of the study, the physicians were expected to report the same laboratory items as those registered at the start of the study. The physicians were able to obtain any information from all registered data shown as figures and to compare the trend of BP changes. The physicians were obligated also to report any adverse effects that occurred during the study. Population enrolment and follow up At the first visit, a total of 88,254 patients received a first prescription of Lo/HCTZ. Of this total, at the end of the present analysis, 24,825 (28%) outpatients had a follow-up visit at 1 month and 20,726 (23%) outpatients had a follow-up visit at 6 months. According to this distribution, clinical data on BP levels, BP control, and responder rates were analyzed only in those patients who had valid data for these parameters at the time of the 238
3 H Suzuki, Y Shimada et al. Figure 1. Flow chart showing the patients in the study. predefined follow up (i.e. 24,825 outpatients for paired comparisons between baseline observation and 1-month follow up, and 20,276 outpatients for paired comparisons between either 1-month and 6-month follow-up visits or baseline visit and 6-month follow up). Obesity was defined as a body mass index of more than 28 kg/m 2. The presence of hypercholesterolemia was defined on the basis of the following diagnostic criteria: serum total cholesterol values exceeding 6.22 mol/l, and/or history of using lipid-lowering drugs. Patients were considered to have DM if they had been diagnosed previously by a doctor, or if they were receiving insulin or oral antidiabetic medications. CKD was defined as an estimated glomerular filtration rate of less than 60 ml/min/1.73 m 2, or having proteinuria. The definition of markers of organ damage was based on recommendations derived from currently available clinical guidelines [Ogihara et al. 2009]. Statistical analysis Data were expressed as mean ± standard deviation. Changes over time in BP were compared between the mean values before and after treatment using Dunnett s test. Any patient having only pretreatment data was excluded from the analysis with Dunnett s test. Continuous variables were compared by using an analysis of variance among groups. All statistical tests were two-sided with an α level of 0.05, and were performed using SAS Release 8.2 (SAS Institute Inc., Cary, NC, USA). Results General characteristics Figure 1 shows a flowchart of the patients. Of 24,825 eligible patients, 20,726 were followed during 6 months. Table 1 shows the general characteristics of the patients. This population was almost equally distributed between males (51.8%) and females (48.2%). The patients were stratified: equal to, or less than 64 years, 9673 (39.0%); years, 7434 (29.9%); equal to or greater than 75 years, 7716 (31.1%). Hypercholesterolemia was the most frequent concomitant CV risk factor (40.1%), followed by DM (25.4%), and obesity (14.5%). CKD with proteinuria (5.2%) and without proteinuria (19.2%) were recorded as the most frequent organ damage markers. Associated clinical conditions, including stroke (10.0%), ischemic heart diseases (8.2%), left ventricular hypertrophy (4.8%), and congestive heart failure (3.8%) were relatively less frequent. All patients eligible for this study received one of the ARBs available in Japan. Physicians discontinued ARBs and started Lo/HCTZ at the start of the study. Half of the patients received ARBs as monotherapy while the others received combination therapy. Changes in BP Average BP reductions during 6 months are shown in Figures 2 6. At the start of the study, the levels of systolic blood pressure (SBP) were significantly highest in the eldest patient group ( 75 years), followed by the years group, and lowest in the youngest patient group ( 64 years). However, at the end of the study, there were no significant differences among the three groups (Figure 3). On the contrary, the levels of diastolic blood pressure (DBP) were significantly highest in the youngest patient group followed by the years group, and lowest in the eldest patient group. These differences in the levels of DBP were maintained throughout the study. Moreover, the average levels of DBP were less than 90 mmhg at the start of the study (Figure 4)
4 Therapeutic Advances in Cardiovascular Disease 6 (6) Table 1. Characteristics of patients. Gender Ages Total % % CKD Male % % Female % <130 mmhg % 64< % mmhg % % SBP mmhg % 75> % mmhg % DM % >180 mmhg 2, % Dyslipidemia % monotherapy % Obesity % Combination % IHD % % LVH % Number of drugs 3 2, % CHF % % Af % % Stroke % % DM, diabetes mellitus; IHD, ischemic heart disease; LVH, left ventricular hypertrophy; CHF, congestive heart failure; Af, atrial fibrillation; CKD, chronic kidney disease; SBP, systolic blood pressure. Figure 2. Changes in blood pressure in response to treatment with losartan/hydrochlorothiazide during the study. Figure 3. Changes in systolic blood pressure in response to treatment with losartan/ hydrochlorothiazide with stratification for age. These data indicated that at the end of the study, the differences in pulse pressure were less than at the start of the study (Figure 5). At the start of the study, the average levels of SBP in females were significantly higher than those in males, but these differences disappeared at the end of the study (Figure 6). Prevalence of target BP The prevalence of hypertensive patients without DM or CKD achieving target SBP control (< 140 mmhg) increased over time from 7.8% to 64.9% (Figure 7). However, the prevalence of hypertensive patients with DM or CKD achieving tight SBP control (< 130 mmhg) increased over time from 3.2% to 24.8%. When stratifying for age, the prevalence of hypertensive patients less than 65 years with DM or CKD achieving tight SBP control (< 130 mmhg) was the lowest among the three groups ( 64 years, 22.5%; years, 26.2%; 75 years, 27.3%). The prevalence of hypertensive patients achieving SBP control (< 140 mmhg) increased over time from 6.9% to 54.3% in females, and 6.1% to 52.3% in males (p < 0.05) (data not shown)
5 H Suzuki, Y Shimada et al. Discussion Lo/HCTZ is the first available fixed-dose combination of antihypertensive drugs available for the clinical management of hypertension. The Website registration system represents an effective tool with which to evaluate BP control in the management of hypertension in a real-life setting [Volpe et al. 2012]. At the time of inclusion in the Web-based registrations, the basal population with hypertension reflected the real-life world. Firstly, male patients slightly outnumbered females. Secondly, those over 75 years of age constituted 30% of the hypertensive population. Thirdly, the prevalence of comorbid diseases was 40% dyslipidemia, 25% DM, 15% obesity, and the remaining included CKD among others. Figure 4. Changes in diastolic blood pressure in response to treatment with losartan/ hydrochlorothiazide with stratification for age. Figure 5. Changes in pulse pressure in response to treatment with losartan/hydrochlorothiazide with stratification for age. Figure 6. Changes in systolic and diastolic blood pressures in response to treatment with losartan/ hydrochlorothiazide in males and females. Gender difference Overall, there was no difference in the effects of Lo/HCTZ on BP between male and female patients. Previously Miller and colleagues demonstrated that men required a larger dose of ARB than women, and that the BP response cannot be used as a surrogate marker for adequate renin angiotensin system (RAS) blockade of the renal microvasculature [Miller et al. 2006]. However, that study was conducted on relatively younger men and women, that is, an average age of 27 years compared with 64 years in this study. According to the data from several large-scale observational studies examining all-cause and CV mortality data [Ostchega et al. 2007; Gu et al. 2008], there are no differences between men and women with respect to deaths per 1000 and the level of SBP. Age stratification Systolic hypertension, the most frequent type of uncontrolled hypertension, is a major risk factor for CV disease. Despite the availability of effective antihypertensive agents, poor control of systolic hypertension appears to be increasing, especially in the older population. In the LIFE trial a subgroup analysis of 1326 elderly patients with isolated hypertension (mean age 70 years, mean BP 174/83 mmhg) showed those patients receiving Lo had significant reductions by 25% of composite endpoints of CV death, stroke, or myocardial infarction compared with the atenolol group [Keating, 2009]
6 Therapeutic Advances in Cardiovascular Disease 6 (6) p r e v a l e n c e Figure 7. Changes in prevalence of target blood pressure during the study in patients with or without CKD and DM with stratification for age. CKD, chronic kidney disease; DM, diabetes mellitus. Lo/HCTZ reduced SBP to a similar level in all age groups in spite of different levels of SBP at the start of the study. In contrast, the levels of DBP were significantly different among the three groups: the 65-year and 75-year age groups showed the highest and lowest levels of DBP, respectively. Lo/HCTZ reduced pulse pressure in the 75-year age group. Based on the previous observations, increases in pulse pressure of more than 60 mmhg resulted in higher CV risk [Franklin et al. 2001; Prisant, 2008]. Until now, these findings may represent the first demonstration that Lo/HCTZ is able to reduce pulse pressure in elderly hypertensive patients. Achievement of target BP Previously, Rump and Sellin examined the effects of treatment with olmesartan (20 mg/day) plus HCTZ (12.5 mg/day), and found that after 12 weeks the proportion of patients with BP < 140/90 mmhg was 43%, which was lower than the 48.1% at week 12 of the present study [Rump and Sellin, 2010]. In our study, patients were followed up longer and 53.2% of patients achieved a BP of < 140/90 mmhg. Similar findings have been reported. The combination of HCTZ (12.5 mg/ day) with either candesartan (8 mg/day) or valsartan (80 mg/day) resulted in approximately 49% of hypertensive patients achieving < 140/90 mmhg with each combination [Mengden et al. 2009]. To achieve adequate BP control in elderly patients is also important. Several studies have reported the target BP achievement rate in elderly hypertensive patients. Saito and colleagues demonstrated that the BP target of < 140/90 mmhg was achieved in a total of 8897 patients in Japan s Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE) study [Saito et al. 2011]. This comprised 57.5% of patients aged years and 56.6% of patients aged 75 years. In the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS) strict treatment to a target BP below 140 mmhg showed no difference in the composite endpoint of CV disease or renal failure, although there was a nonsignificant trend towards a higher all-cause mortality rate [JATOS, 2008; Kawano et al. 2011],. Similar findings were reported in over 3000 elderly hypertensive patients, that is, strict control (target SBP < 140 mmhg) was not superior to moderate SBP control (target SBP mmhg) in reducing a composite CV endpoint [Okin et al. 2012]. In the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study [Shimamoto et al. 2008], BP was controlled at < 140/90 mmhg in 46% of patients. Kushiro and colleagues showed that administration of olmesartan in elderly hypertensive patients resulted in the control of BP at < 140/90 mmhg in 49.8% [Kushiro et al. 2009]
7 H Suzuki, Y Shimada et al. In the present study, the levels were similar between the patients with and without DM. In general, high BP is prevalent in diabetic patients. In addition, an estimated 35 75% of CV and renal complications of DM can be attributed to high BP [Hillier and Pedula, 2001]. The benefits of reducing BP to the recommended goal of < 130/85 mmhg in diabetic patients are clear. However, previous statistics reported that only 11% of those with type 2 DM treated for hypertension achieved the recommended BP goal of < 130/85 mmhg [Bakris, 2001]. Recently, Bakris and colleagues demonstrated that amlodipine/ benazepril (5/10 mg combination) achieved the treatment goal of < 130/85 mmhg in 63% of the patients, and when HCTZ (12.5 mg) was added, the achievement rate increased to 89% [Bakris et al. 2008]. The achievement rate of this study was less than these reported figures, indicating that RAS inhibition with calcium channel blockers might be more powerful in reducing BP of patients with DM than RAS inhibition with thiazide diuretics. Limitations The lack of a case-control (placebo) design in the analysis may have in part affected our findings, particularly when relating to safety and tolerability. The large sample size and different distribution of registered physicians may also mean that the views expressed by respondents may not be fully representative of behaviors across the entire physician community. In addition, the use of electronic support may have included only those physicians who had easy access to the Web database, rather than to all physicians. This was a fully observational study, and during the course of the follow-up period, a large number of patients did not return to the prescribing physicians. For this reason, the number of the patients with available data at follow-up visits is limited. This Web-based system will generate a representative and updated database of postmarketing surveillance aimed at improving CV protection and preserving the quality of life for patients with different CV risk profiles. In conclusion, firstly, the Web-based system provides useful information when a new drug is released on to the market. Secondly, treatment with Lo/HCTZ enabled a substantial proportion of elderly hypertensive patients to achieve the recommended BP goal of < 140/90 mmhg. Moreover, in patients of aged 75 years, this drug combination resulted in a reduction of < 60 mmhg in pulse pressure. However, only 25% of diabetic patients achieved the target BP < 130/85 mmhg, indicating that add-on therapy will be needed in those patients. Funding This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. Conflict of interest statement The authors have never had any involvement that might raise the question of bias in the work reported or in the conclusions, implications, or opinions stated. References Bakris, G. (2001) A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 161: Bakris, G., Hester, A., Weber, M., Dahlöf, B., Pitt, B., Velasquez, E. et al. (2008) The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. J Cardiometab Syndr 3: Boersma, E., Keil, U., De Bacquer, D., De Backer, G., Pyorala, K., Poldermans, D. et al. (2003) Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 21: Bramlage, P., Thoenes, M., Kirch, W. and Lenfant, C. (2007) Clinical practice and recent recommendations in hypertension management reporting a gap in a global survey of 1259 primary care physicians in 17 countries. Curr Med Res Opin 23: Dahlöf, B., Devereux, R., Kjeldsen, S., Julius, S., Beevers, G., de Faire, U. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE); a randomised trial against atenolol. Lancet 359: Dusing, R. (2010) Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag 6: Franklin, S., Jacobs, M., Wong, N., L Italien, G. and Lapuerta, P. (2001) Predominance of isolated systolic hypertension among middle-aged and elderly 243
8 Therapeutic Advances in Cardiovascular Disease 6 (6) Visit SAGE journals online SAGE journals US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37: Gu, Q., Burt, V., Paulose-Ram, R. and Dillon, C. (2008) Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey Am J Hypertens 21: Hillier, T. and Pedula, K. (2001) Characteristics of an adult population with newly diagnosed type 2 diabetes. Diabetes Care 24: JATOS (2008) Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 31: Kawano, Y., Ogihara, T., Saruta, T., Goto, Y. and Ishii, M. (2011) Association of blood pressure control and metabolic syndrome with cardiovascular risk in elderly Japanese: JATOS study. Am J Hypertens 24: Keating, G. (2009) Losartan/hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 69: Kushiro, T., Saito, I., Hirata, K., Ishikawa, M., Yamashita, T., Matsushita, Y. et al. (2009) Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan. Clin Exp Hypertens 31: Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: Mengden, T., Uen, S. and Bramlage, P. (2009) Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility. Vasc Health Risk Manag 5: Miller, J., Cherney, D., Duncan, J., Lai, V., Burns, K., Kennedy, C. et al. (2006) Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol 17: Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M. et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32: Okin, P., Hille, D., Kjeldsen, S., Dahlof, B. and Devereux, R. (2012) Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens 30: ; discussion 810. Ostchega, Y., Dillon, C., Hughes, J., Carroll, M. and Yoon, S. (2007) Trends in hypertension prevalence, awareness, treatment, and control in older US adults: data from the National Health and Nutrition Examination Survey 1988 to J Am Geriatr Soc 55: Prisant, L. (2008) Now or never: optimal antihypertensive therapy in the elderly. Prev Cardiol 11: Rump, L. and Sellin, L. (2010) Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide. Expert Opin Pharmacother 11: Saito, I., Suzuki, H., Kageyama, S. and Saruta, T. (2011) Treatment of hypertension in patients 85 years of age or older: a J-BRAVE substudy. Clin Exp Hypertens 33: Sawicki, P. and McGauran, N. (2006) Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care? Hypertension 48: 1 7. Shimamoto, K., Fujita, T., Ito, S., Naritomi, H., Ogihara, T., Shimada, K. et al. (2008) Impact of blood pressure control on cardiovascular events in 26,512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res 31: Sica, D. (2006) Angiotensin receptor blockers: new considerations in their mechanism of action. J Clin Hypertens (Greenwich) 8: Volpe, M., Tocci, G., Bianchini, F., De Rosa, M., Fedozzi, E., Covezzoli, A. et al. (2012) Use of aliskiren in a real-life model of hypertension management: analysis of national Web-based drug-monitoring system in Italy. J Hypertens 30:
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationEfficacy and Safety of a Single-Pill Fixed-Dose Combination of Azilsartan and Amlodipine
Elmer ress Original Article J Clin Med Res. 2016;8(12):888-892 Efficacy and Safety of a Single-Pill Fixed-Dose Combination of Azilsartan and Amlodipine Kota Motozato a, b, Shin-ichiro Miura a, c, d, Yuhei
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationEffectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine
831 Original Article Hypertens Res Vol.3 (27) No.9 p.831-837 Effectiveness of Add-On Low-Dose Diuretics in Combination Therapy for Hypertension: Losartan/Hydrochlorothiazide vs. Candesartan/Amlodipine
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationRationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC
Rationale for the use of Single Pill Combination (SPC) and Asian data of ARB/CCB SPC Seung Woo Park, MD Samsung Medical Center BP Control Rates in Asia BP controlled BP uncontrolled 24.3% 36.6% 19% Turkey
More informationBlood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial
Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationMethods. Study design
Elmer ress Original Article J Clin Med Res. 2017;9(2):98-103 Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationChapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,
Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationExplore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management
Explore the Rationale for the Dual Mechanism CCB/ARB Approach in Hypertension Management Jeong Bae Park, MD,PhD Dept of Med/Cardiology, Cheil General Hospital, Kwandong University College of Medicine Apr
More informationClinical cases with Coversyl 10 mg
Clinical cases Coversyl 10 mg For upgraded benefits in hypertension A Editorial This brochure, Clinical cases Coversyl 10 mg for upgraded benefits in hypertension, illustrates a variety of hypertensive
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Blood Pressure Control role of specific antihypertensives
Blood Pressure Control role of specific antihypertensives Date written: May 2005 Final submission: October 2005 Author: Adrian Gillian GUIDELINES a. Regimens that include angiotensin-converting enzyme
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationCombination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London
Combination therapy Giuseppe M.C. Rosano, MD, PhD, MSc, FESC, FHFA St George s Hospitals NHS Trust University of London KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email:
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More informationRationale for the use of Single Pill Combination. Yong Jin Kim, MD Seoul National University Hospital
Rationale for the use of Single Pill Combination Yong Jin Kim, MD Seoul National University Hospital Unmet Need of Hypertension Treatment Hypertension # 1 Risk Factor for Global Mortality 0 1 2 3 4 5 6
More informationHiroyuki Daikuhara 1, Fumi Kikuchi 2 and Toshihiko Ishida 2. Introduction. Original Article
447310DVR9410.1177/1479164112447310Daikuhara et al.diabetes and Vascular Disease Research 2012 Original Article The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan
More informationAntihypertensive efficacy of olmesartan compared with other antihypertensive drugs
(2002) 16 (Suppl 2), S24 S28 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh compared with other antihypertensive drugs University Clinic Bonn, Department of Internal
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationThe Hypertension Clinic is a part of the Internal Medicine
Original Article Hypertension Registry at the Bangkok Hospital Medical Center: The First 7 Months Experience OBJECTIVE: The Hypertension Registry at the Bangkok Hospital Medical Center was established
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationValsartan Amlodipine HCT Combination: Control To Goal. Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI. Prof of cardiology Ain Shams University
Valsartan Amlodipine HCT Combination: Control To Goal Dr. Sameh Shaheen M.B.B.Ch, MSc, MD, FESC, FSCAI Prof of cardiology Ain Shams University Sonesta Hotel Cairo Egypt December 4 th 5 th ; 213 Hypertension
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationDon t let the pressure get to you:
Balanced information for better care Don t let the pressure get to you: Current evidence-based goals for treating hypertension A cornerstone of primary care: Lowering high blood pressure prevents cardiovascular
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationCharacteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study
ORIGINAL PAPER Characteristics and Future Cardiovascular Risk of Patients With Not-At- Goal Hypertension in General Practice in France: The AVANT AGE Study Yi Zhang, MD, PhD; 1 Helene Lelong, MD; 2 Sandrine
More informationPrevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients
Original Paper Prevalence of Comorbidities and Their Influence on Blood Pressure Goal Attainment in Geriatric Patients CME Credit 1 www.lejacq.com/cme John D. Bisognano, MD, PhD; 1 Kevin A. Townsend, MS,
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationVal-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp
Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationKey Words: losartan, hypertension, blood pressure, cardiovascular disease, observational study
469 Original Article Hypertens Res Vol.31 (2008) No.3 p.469-478 Impact of Blood Pressure Control on Cardiovascular Events in 26,512 Japanese Hypertensive Patients: The Japan Hypertension Evaluation with
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationAmlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy
ORIGINAL ARTICLE Korean J Intern Med 2014;29:315-324 and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy Seung-Ah Lee 1,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationIn patients with severe hypertension, the shortterm
Review Paper The Risks and Benefits of Initial Irbesartan Hydrochlorothiazide Combination Therapy in Patients With Severe Hypertension Pablo Lapuerta, MD; 1 * Stanley Franklin, MD 2 The impact of delays
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationABSTRACT ORIGINAL RESEARCH. Joel Neutel Ali Shojaee Jen-Fue Maa. Adv Ther (2012) 29(6): DOI /s z
Adv Ther (212) 29(6):58 523. DOI 1.17/s12325-12-3-z ORIGINAL RESEARCH Efficacy of Amlodipine/Olmesartan ± Hydrochlorothiazide in Patients Uncontrolled on Prior Calcium Channel Blocker or Angiotensin II
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationHypertension in the Elderly. John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care
Hypertension in the Elderly John Puxty Division of Geriatrics Center for Studies in Aging and Health, Providence Care Learning Objectives Review evidence for treatment of hypertension in elderly Consider
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHow clinically important are the results of the large trials in hypertension?
How clinically important are the results of the large trials in hypertension? Stéphane LAURENT, MD, PhD, FESC Pharmacology Department and PARCC / INSERM U970 Hôpital Européen Georges Pompidou, Université
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationJournal of the American College of Cardiology Vol. 44, No. 6, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 6, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.034
More informationORIGINAL ARTICLE. S Oparil 1, SG Chrysant 2, M Melino 3, J Lee 3, S Karki 3 and R Heyrman 3 1. Introduction
(2010) 24, 831 838 & 2010 Macmillan Publishers Limited All rights reserved 0950-9240/10 www.nature.com/jhh ORIGINAL ARTICLE Long-term efficacy of a combination of amlodipine and olmesartan medoxomil±hydrochlorothiazide
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationHypertension Management: Making Sense of Guidelines and Therapy Options for the Elderly
Butler University Digital Commons @ Butler University Scholarship and Professional Work COPHS College of Pharmacy & Health Sciences 2015 Hypertension Management: Making Sense of Guidelines and Therapy
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationThe control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS
REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood
More informationBlood Pressure Monitoring in Chronic Kidney Disease
Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More informationFerrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1Overview of disease epidemiology 1 Losartan is indicated for: Treatment of essential hypertension in adults and in children and adolescent 6 18 years of age. Treatment
More informationBlood Pressure Targets in Diabetes
Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet
More informationThe underestimated risk of
Earn 3 CPD Points online The underestimated risk of hypertension Dr David Webb Johannesburg Introduction The high and increasing worldwide burden of hypertension is a major global health challenge. Hypertension
More information